Barchart Research What to Expect from IMCR Earnings IMCR Generated May 5, 2026 Current Price $28.84 EPS Estimate $$-0.26 Consensus Rating Moderate Buy Average Move 3.12% Immunocore's Pipeline Expansion...
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Immunocore Holdings, with a price target of $100.00. The company’s shares opened today at $31.80.Elevate Your...
Puma Biotechnology PBYI reported second-quarter 2025 adjusted earnings of 15 cents per share, which beat the Zacks Consensus Estimate of 11 cents. In the year-ago quarter, the company had incurred an...
Mirum Pharmaceuticals MIRM reported a loss of 12 cents per share for the second quarter of 2025, much narrower than the Zacks Consensus Estimate of a loss of 31 cents. The company had incurred a loss...
Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company had reported earnings...
Catalyst Pharmaceuticals CPRX reported adjusted earnings of 68 cents per share for the second quarter of 2025, beating the Zacks Consensus Estimate of 58 cents. The company had recorded adjusted earnings...
ADMA Biologics (ADMA) reported better-than-expected results for the second quarter. Adjusted earnings per share of 15 cents beat the Zacks Consensus Estimate by a penny.Revenues of $122 million (up 14%...
Esperion Therapeutics ESPR incurred a loss of 2 cents per share in the second quarter of 2025, which was much narrower than the Zacks Consensus Estimate of a loss of 17 cents. The company had incurred...
Recursion Pharmaceuticals RXRX reported a loss of 41 cents per share in the second quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 35 cents. The company had incurred a loss of 40...
Beam Therapeutics BEAM incurred a loss of $1.00 per share in the second quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of $1.04. The company had reported a loss of $1.11...